SAN DIEGO--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the availability of Empirica™ Study, formerly the Clinical Trials Signal Detection product (CTSD™). The Empirica Study solution helps clinical and safety teams improve their understanding of a product’s emerging safety profile during clinical development by facilitating the timely detection, review and analysis of safety issues in clinical trials data.
